{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:06:32Z","timestamp":1790075192163,"version":"4.0.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["DI-2024-00112"],"award-info":[{"award-number":["DI-2024-00112"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:p>\n                    Sepsis remains a diagnostic challenge because early clinical manifestations are non-specific and microbiological confirmation often arrives too late to guide first-hour decisions. The 2026 Surviving Sepsis Campaign guidelines reinforce early clinical recognition using validated clinical scores, appropriate diagnostic strategies, and responsible antimicrobial use and de-escalation. Yet, initial management still frequently occurs under diagnostic uncertainty. Hundreds of biomarkers have been proposed to improve sepsis diagnosis, risk stratification and treatment guidance; however, only a limited subset has progressed from discovery to regulated\n                    <jats:italic>in vitro<\/jats:italic>\n                    diagnostic use. This Mini Review examines selected sepsis biomarkers and diagnostic platforms with emphasis on technologies that have reached certified or cleared IVD implementation, or that illustrate a credible route toward regulated use. We discuss conventional soluble biomarkers such as procalcitonin, C-reactive protein, interleukin-6 and lactate; emerging severity and host-response markers including presepsin, pancreatic stone protein, monocyte distribution width and mid-regional proadrenomedullin; transcriptomic and cellular host-response tests; and functional immune technologies such as the LPS-induced TNF-alpha release assay, also referred to as TARA. Rather than ranking biomarkers solely by diagnostic performance, we emphasize intended clinical use, biological rationale, sample type, turnaround time, regulatory status and workflow compatibility. The review highlights the persistent gap between biomarker discovery and clinical deployment, set against an evolving regulatory landscape shaped by the EU IVDR and the phased rollout of EUDAMED. Future sepsis diagnostics will likely move beyond isolated inflammatory analytes toward integrated host-response, near-patient and functional immune assays able to support early triage, risk stratification, antimicrobial stewardship and precision immune monitoring.\n                  <\/jats:p>","DOI":"10.3389\/fmedt.2026.1916860","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:31:35Z","timestamp":1790073095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From sepsis biomarker discovery to regulated in vitro diagnostics: evidence, certification status and implementation gaps"],"prefix":"10.3389","volume":"8","author":[{"given":"Erika P.","family":"Plata-Menchaca","sequence":"first","affiliation":[{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]},{"name":"Medicine ICU Department, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Hern\u00e1ndez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Loop Diagnostics S.L., StartUB!\u2014University of Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00134-026-08361-1","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2026","volume":"52","author":"Prescott","year":"2026","journal-title":"Intensive Care Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00540-012-1502-7","article-title":"Clinical application of sepsis biomarkers","volume":"27","author":"Sankar","year":"2013","journal-title":"J Anesth"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3947\/ic.2014.46.1.1","article-title":"Biomarkers of sepsis","volume":"46","author":"Cho","year":"2014","journal-title":"Infect Chemother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5492\/wjccm.v12.i4.188","article-title":"Biomarkers in sepsis: looking for the holy grail or chasing a mirage!","volume":"12","author":"Ahuja","year":"2023","journal-title":"World J Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9010","DOI":"10.3390\/ijms25169010","article-title":"Sepsis biomarkers: advancements and clinical applications: a narrative review","volume":"25","author":"He","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","volume-title":"De Novo Classification Request for Sepsis ImmunoScore, DEN230036","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0181704","DOI":"10.1371\/journal.pone.0181704","article-title":"Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis","volume":"12","author":"Ljungstr\u00f6m","year":"2017","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/cid\/ciaf336","article-title":"Reassessing procalcitonin-guided antibiotic therapy in critically ill patients with sepsis: lessons from the ADAPT-sepsis trial","volume":"82","author":"Gupta","year":"2026","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12879-023-08262-4","article-title":"Comparison of presepsin and mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis","volume":"23","author":"Liang","year":"2023","journal-title":"BMC Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2217\/bmm-2019-0174","article-title":"Prognostic performance of pancreatic stone protein in critically ill patients with sepsis","volume":"13","author":"Garc\u00eda de Guadiana-Romualdo","year":"2019","journal-title":"Biomark Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.18103\/mra.v11i12.4893","article-title":"Pancreatic stone protein measurement to screen and diagnose sepsis in the context of the surviving sepsis campaign recommendations","volume":"11","author":"Ventura","year":"2024","journal-title":"Med Res Arch"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s15010-023-02093-w","article-title":"Discriminative performance of pancreatic stone protein in predicting ICU mortality and infection severity in adult patients with infection: a systematic review and individual patient level meta-analysis","volume":"51","author":"Zuercher","year":"2023","journal-title":"Infection"},{"key":"B15","volume-title":"IVD CAPSULE PSP; abioSCOPE: 510(k) Premarket Notification K240041","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1515\/cclm-2021-1331","article-title":"Monocyte distribution width (MDW) as a screening tool for early detecting sepsis: a systematic review and meta-analysis","volume":"60","author":"Agnello","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B17","volume-title":"UniCel DxH 800 Cellular Analysis System with Early Sepsis Indicator Application: 510(k) Premarket Notification K181599","year":"2019"},{"key":"B18","volume-title":"SeptiCyte RAPID: 510(k) Premarket Notification K203748","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69:hvad097.340","DOI":"10.1093\/clinchem\/hvad097.340","article-title":"A-384 laboratory evaluation of the SeptiCyte RAPID host response assay in differentiating infection-positive versus infection-negative systemic inflammation patients suspected of sepsis","author":"Sankari","year":"2023","journal-title":"Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-4939-1776-1_15","article-title":"Host response biomarkers in the diagnosis of sepsis: a general overview","volume":"1237","author":"Parlato","year":"2015","journal-title":"Methods Mol Biol"},{"key":"B21","volume-title":"TriVerity: 510(k) Summary K241676","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e00352","DOI":"10.1128\/jcm.00352-25","article-title":"Analytical evaluation of TriVerity, a rapid diagnostic and prognostic host gene expression test performed on the Myrna instrument using RT-LAMP","volume":"63","author":"Figueiredo-Pereira","year":"2025","journal-title":"J Clin Microbiol"},{"key":"B23","volume-title":"IntelliSep Test: 510(k) Premarket Notification K220991","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/acem.14923","article-title":"Cellular host response sepsis test for risk stratification of patients in the emergency department: a pooled analysis","volume":"31","author":"O'Neal","year":"2024","journal-title":"Acad Emerg Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/cc5055","article-title":"Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis","volume":"10","author":"Cavaillon","year":"2006","journal-title":"Crit Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0182427","DOI":"10.1371\/journal.pone.0182427","article-title":"Human leucocyte antigen HLA-DR gene expression is reduced in sepsis and correlates with impaired TNF-\u03b1 response: a diagnostic tool for immunosuppression?","volume":"12","author":"Winkler","year":"2017","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/SHK.0000000000001915","article-title":"Functional transcriptomic studies of immune responses and endotoxin tolerance in early human sepsis","volume":"57","author":"Leligdowicz","year":"2022","journal-title":"Shock"},{"key":"B28","doi-asserted-by":"publisher","first-page":"891024","DOI":"10.3389\/fimmu.2022.891024","article-title":"Advances in immune monitoring approaches for sepsis-induced immunosuppression","volume":"13","author":"Yao","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-physiol-061121-040214","article-title":"Sepsis-induced immunosuppression","volume":"84","author":"Torres","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.chstcc.2023.100029","article-title":"Ex vivo endotoxin stimulation of blood for predicting survival in patients with sepsis: a systematic review","volume":"1","author":"Wheelwright","year":"2023","journal-title":"CHEST Crit Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1447523","DOI":"10.3389\/fimmu.2024.1447523","article-title":"Assessing sepsis-induced immunosuppression to predict positive blood cultures","volume":"15","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2024","journal-title":"Front Immunol"},{"key":"B32","volume-title":"SeptiLoop\u00ae Instructions for Use, SL001, CE English Version 022","year":"2025"},{"key":"B33","doi-asserted-by":"publisher","first-page":"AIoa2400867","DOI":"10.1056\/AIoa2400867","article-title":"FDA-authorized AI\/ML tool for sepsis prediction: development and validation","volume":"1","author":"Bhargava","year":"2024","journal-title":"NEJM AI"},{"key":"B34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00134-019-05872-y","article-title":"Machine learning for the prediction of sepsis: a systematic review and meta-analysis of diagnostic test accuracy","volume":"46","author":"Fleuren","year":"2020","journal-title":"Intensive Care Med"},{"key":"B35","first-page":"176","article-title":"Regulation (EU) 2017\/746 of the European parliament and of the council of 5 April 2017 on in vitro diagnostic medical devices and repealing directive 98\/79\/EC and commission decision 2010\/227\/EU","year":"2017","journal-title":"Off J Eur Union"},{"key":"B36","volume-title":"The EUDAMED Four First Modules Will be Mandatory to use as from 28 May 2026","year":"2025"}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1916860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:31:37Z","timestamp":1790073097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1916860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":36,"alternative-id":["10.3389\/fmedt.2026.1916860"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2026.1916860","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1916860"}}